Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group Study to Evaluate the Safety and Efficacy of Intravenous Natalizumab (BG00002) on Reducing Infarct Volume in Acute Ischemic Stroke

Next Previous
Trial Profile

A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group Study to Evaluate the Safety and Efficacy of Intravenous Natalizumab (BG00002) on Reducing Infarct Volume in Acute Ischemic Stroke

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 21 Oct 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Natalizumab (Primary)
  • Indications Ischaemic stroke
  • Focus Proof of concept; Therapeutic Use
  • Acronyms ACTION
  • Sponsors Biogen

Most Recent Events

  • 21 Mar 2020 Results (n=159) assessing exposure response analysis of natalizumab in subjects with acute Ischemic Stroke, presented at the 121st Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
  • 21 Apr 2016 Results presented at the 68th Annual Meeting of the American Academy of Neurology
  • 19 Feb 2016 Primary endpoint of relative change in infarct growth from baseline to day 5 assessed by MRI has not been met, according to results presented at the 41st International Stroke Conference.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top